Hyperlipidemia - PACE-CME

Episodes 17-32 of 43

What do we know now that could have changed the history of CETP inhibition?: genetics and biology
What do we know now that could have changed the history of CETP inhibition?: genetics and biology
MinuteCE®
What do we know now that could have changed the history of CETP inhibition?: genetics and biology
0.50 program credits
- Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
0.50 program credits
Managing a patient with residual risk: Applying recent evidence with EPA to practice
Managing a patient with residual risk: Applying recent evidence with EPA to practice
MinuteCE®
Managing a patient with residual risk: Applying recent evidence with EPA to practice
0.50 program credits
- Prof. Kausik Ray
0.50 program credits
MinuteCE®
Innovating the clinical management of LDL-c: Exploring CETP as therapeutic target
0.50 credits 3 episodes
- Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
- Erin Michos
0.50 credits 3 episodes
Integrating EPA in CV risk reduction strategies: Practical experience and guidance
Integrating EPA in CV risk reduction strategies: Practical experience and guidance
MinuteCE®
Integrating EPA in CV risk reduction strategies: Practical experience and guidance
0.50 program credits
- Azfar Zaman, MD
0.50 program credits
CETP inhibition: Lessons from two decades of clinical trials
CETP inhibition: Lessons from two decades of clinical trials
MinuteCE®
CETP inhibition: Lessons from two decades of clinical trials
0.50 program credits
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
0.50 program credits
Understanding the role of triglycerides in the assessment of residual risk
Understanding the role of triglycerides in the assessment of residual risk
MinuteCE®
Understanding the role of triglycerides in the assessment of residual risk
0.50 program credits
- Prof. Alberto Zambon MD, PhD, FAHA
0.50 program credits
MinuteCE®
Clinical scenarios addressing residual risk in ASCVD: Understanding the role of triglycerides and EPA
0.50 credits 3 episodes
- Prof. Alberto Zambon MD, PhD, FAHA
- Kausik Ray, MBChB, MD, MPhil
- Azfar Zaman, MD
0.50 credits 3 episodes
A novel CETP inhibitor to target CV risk reduction: Where could it fit in future lipid management?
A novel CETP inhibitor to target CV risk reduction: Where could it fit in future lipid management?
MinuteCE®
A novel CETP inhibitor to target CV risk reduction: Where could it fit in future lipid management?
0.50 program credits
- Erin Michos
0.50 program credits
ACC 2024: SHASTA-2 Final Study Results
ACC 2024: SHASTA-2 Final Study Results
MinuteCE®
ACC 2024: SHASTA-2 Final Study Results
0.75 program credits
- Daniel Gaudet, MD, PhD
0.75 program credits
Plozasiran (ARO-APOC3) Decreases APOC3 and Triglycerides (TG) in Patients With Mixed Hyperlipidemia: MUIR Final Results
Plozasiran (ARO-APOC3) Decreases APOC3 and Triglycerides (TG) in Patients With Mixed Hyperlipidemia: MUIR Final Results
MinuteCE®
Plozasiran (ARO-APOC3) Decreases APOC3 and Triglycerides (TG) in Patients With Mixed Hyperlipidemia: MUIR Final Results
0.75 program credits
- Christie Ballantyne, MD
0.75 program credits
MinuteCE®
Improving the management of patients with atherosclerotic cardiovascular disease - The evolving role of icosapent ethyl
1.00 credit 3 episodes
- Erik Stroes
- P. Gabriel Steg, MD
- Pam R. Taub, MD, FACC, FASPC
1.00 credit 3 episodes
Challenges in ASCVD reduction and TG-related risk
Challenges in ASCVD reduction and TG-related risk
MinuteCE®
Challenges in ASCVD reduction and TG-related risk
1.00 program credit
- Erik Stroes
1.00 program credit
Perspectives on the results of recent clinical outcomes trials with EPA prevention
Perspectives on the results of recent clinical outcomes trials with EPA prevention
MinuteCE®
Perspectives on the results of recent clinical outcomes trials with EPA prevention
1.00 program credit
- P. Gabriel Steg, MD
1.00 program credit
Integrating icosapent ethyl in cardiovascular risk reduction strategies: Practical guidance
Integrating icosapent ethyl in cardiovascular risk reduction strategies: Practical guidance
MinuteCE®
Integrating icosapent ethyl in cardiovascular risk reduction strategies: Practical guidance
1.00 program credit
- Pam R. Taub, MD, FACC, FASPC
1.00 program credit
Oral cholesterol-lowering therapies: The basis of prevention
Oral cholesterol-lowering therapies: The basis of prevention
MinuteCE®
Oral cholesterol-lowering therapies: The basis of prevention
1.00 program credit
- Lale Tokgözoğlu, MD
1.00 program credit
PCSK9i: Benefits across the spectrum of cardiovascular disease
PCSK9i: Benefits across the spectrum of cardiovascular disease
MinuteCE®
PCSK9i: Benefits across the spectrum of cardiovascular disease
1.00 program credit
- Fabrice Martens
1.00 program credit

2/3